Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CCR2 | P41597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5243645 | 0.93 | — | — | |
| SCHEMBL10326679 | 0.80 | CYP2D6 (0.34) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL1547510 | 0.80 | CYP2D6 (0.34) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL3229383 | 0.80 | CYP2D6 (0.34) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL24922624 | 0.78 | CYP2D6 (0.33) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL797872 | 0.78 | CYP2D6 (0.33) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL22260036 | 0.78 | CYP2D6 (0.33) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL16448784 | 0.76 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL4380928 | 0.76 | KDM4E (0.32) | KDM4ENPC1CYP1A2CYP2D6HPGD | |
| SCHEMBL20833338 | 0.76 | KDM4E (0.40) | KDM4ENPC1CYP1A2CYP2D6HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569638-B1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-7084169-B2 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1569638-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | ROCHE PALO ALTO LLC (US) | 2004-07-08 | — | — | US | disclosed |
| WO-2004050085-A1 | AMINOALKOXYINDOLES AS 5-HT6-RECEPTOR LIGANDS FOR THE TREATMENT OF CNS-DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132799-A1 | Aminoalkoxyindoles and methods of use | HTR3C, HTR2C, CYP3A5 | KDM4E 881/4885NPC1 841/4885CYP1A2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.